SignALS
SignALS is a feed of ALS and MND news without the fluff. Quick, plain summaries of new research, treatments, and stories, with links if you want to dive deeper.
ALS Reversals: New Paths
Oct 30, 2025Dr. Bedlack’s team studies Amyotrophic Lateral Sclerosis (ALS) reversals to understand why a few people regain function. The St.A.R. program looks back for clues, while R.O.A.R. tests reversal-linked therapies in small, open trials. New work on the gut with microbiota transplant therapy (FMT) and a beta-Hydroxy beta-Methylbutyrate (HMB) supplement seeks personalized paths to slow or reverse ALS, guided by science and hope.
Italy cannabis ALS trial
Oct 29, 2025Italy has enrolled the first participant in a 3-year Phase 2 trial of Avextra’s cannabis medicine for Amyotrophic Lateral Sclerosis (ALS), Parkinson’s, and Alzheimer's. The 180-person study will compare a standardized full-spectrum extract to placebo to check safety and whether it eases symptoms and improves daily life. For ALS, the goal is less pain, better sleep, and steadier mood.